Download PDF
Semin intervent Radiol 2013; 30(01): 067-073
DOI: 10.1055/s-0033-1333655
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Irreversible Electroporation of Hepatic Malignancy

Govindarajan Narayanan
1   Miller School of Medicine, University of Miami, Miami, Florida
,
Tatiana Froud
1   Miller School of Medicine, University of Miami, Miami, Florida
,
Rekhaben Suthar
1   Miller School of Medicine, University of Miami, Miami, Florida
,
Katuska Barbery
1   Miller School of Medicine, University of Miami, Miami, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
27 February 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) is a worldwide problem of epidemic proportions, best treated in a multidisciplinary setting. Major advances have been made in all specialties that manage patients with HCC, with surgical options at one end of the spectrum and palliative chemotherapy on the other, and the vast majority of patients require the involvement and expertise of interventional oncology. Several ablative and transarterial technologies are currently available. Irreversible electroporation (IRE) is a new ablative technology that uses high-voltage, low-energy DC current to create nanopores in the cell membrane, disrupting the homeostasis mechanism and inducing cell death by initiating apoptosis. This article discusses the evolution of IRE as well as its safety and efficacy in the context of other ablative therapies in the treatment of hepatic malignancies.

Keywords

irreversible electroporation (IRE) - NanoKnife - hepatocellular carcinoma (HCC) ablation - apoptosis
 

  • References

  • 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2) 74-108
    Google Scholar
  • 2 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 01) S20-S37
    PubMedGoogle Scholar
  • 3 Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5) (Suppl. 01) S5-S16
    CrossrefPubMedGoogle Scholar
  • 4 Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 2004; 127 (5) (Suppl. 01) S1-S4
    CrossrefPubMedGoogle Scholar
  • 5 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127 (5) 1372-1380
    CrossrefPubMedGoogle Scholar
  • 6 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54 (4) 533-539
    CrossrefPubMedGoogle Scholar
  • 7 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
    CrossrefPubMedGoogle Scholar
  • 8 Rodrıguez de Lope C, Tremosini S, Forner A , et al. Management of HCC. J Hepatol 2012; 56 (6) 1317-1323
    CrossrefPubMedGoogle Scholar
  • 9 Figueras J, Jaurrieta E, Valls C , et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190 (5) 580-587
    CrossrefPubMedGoogle Scholar
  • 10 Yao FY, Bass NM, Nikolai B , et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8 (10) 873-883
    CrossrefPubMedGoogle Scholar
  • 11 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5) 1208-1236
    CrossrefPubMedGoogle Scholar
  • 12 Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49 (2) 453-459
    CrossrefPubMedGoogle Scholar
  • 13 Teratani T, Yoshida H, Shiina S , et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43 (5) 1101-1108
    CrossrefPubMedGoogle Scholar
  • 14 Mahvi DM, Lee Jr FT. Radiofrequency ablation of hepatic malignancies: is heat better than cold?. Ann Surg 1999; 230 (1) 9-11
    CrossrefPubMedGoogle Scholar
  • 15 Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities—part I. J Vasc Interv Radiol 2001; 12 (9) 1021-1032
    CrossrefPubMedGoogle Scholar
  • 16 Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-845
    PubMedGoogle Scholar
  • 17 Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987; 78 (12) 1319-1321
    PubMedGoogle Scholar
  • 18 Mir LM, Orlowski S, Belehradek Jr J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27 (1) 68-72
    CrossrefPubMedGoogle Scholar
  • 19 Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33 (2) 223-231
    CrossrefPubMedGoogle Scholar
  • 20 Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 2007; 6 (1) 37-48
    CrossrefPubMedGoogle Scholar
  • 21 Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010; 255 (2) 426-433
    CrossrefPubMedGoogle Scholar
  • 22 Thomson KR, Cheung W, Ellis SJ , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (5) 611-621
    CrossrefPubMedGoogle Scholar
  • 23 Narayanan G, Froud T, Lo K, Barbery KJ, Perez-Rojas E, Yrizarry J. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation—initial observations. Cardiovasc Intervent Radiol 2012; ; June 30 (Epub ahead of print)
    PubMedGoogle Scholar
  • 24 Kingham TP, Karkar AM, D'Angelica MI , et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (3) 379-387
    CrossrefPubMedGoogle Scholar
  • 25 Narayanan G, Hosein P, Arora G, Barbery KJ, Yrizarry J. Percutaneous irreversible electroporation (ire) in the treatment of HCC and metastatic colorectal cancer (MCRC) to the liver. J Vasc Interv Radiol 2012; 23 (12) 1613-1621
    CrossrefPubMedGoogle Scholar
  • 26 El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5) (Suppl. 01) S27-S34
    CrossrefPubMedGoogle Scholar
  • 27 El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139 (10) 817-823
    CrossrefPubMedGoogle Scholar